Natco Pharma launches Everolimus tablets in the US

Our Bureau Updated - October 01, 2021 at 04:45 PM.

The drug is generally indicated for the treatment of certain types of cancer

A private security guard looks out from a window of the head office of Natco in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH BUSINESS)

Natco Pharma Ltd ‘s marketing partner, Breckenridge Pharmaceutical, Inc., US has launched the Everolimus Tablets 10mg, a generic version for Afinitor, in the US market.

The US Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application. The drug is generally indicated for the treatment of certain types of cancer.

According to industry sales data, the 10 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market, the Hyderabad-based company said in a release.

Published on October 1, 2021 10:23